NGeneBio announced the launch of Korea's first large-scale gene fusion diagnostic panel for solid tumors, called "ONCOaccuPanel RNA," designed to precisely diagnose gene fusion mutations in cancer patients.

Developed through technology transferred from Asan Medical Center, ONCOaccuPanel RNA utilizes next-generation sequencing (NGS) to detect gene fusion mutations with high sensitivity and accuracy.

Unlike traditional diagnostic methods, this panel is capable of identifying mutations across 145 genes in a single test, enabling efficient, precise diagnostics. It is also compatible with NGeneBio’s existing DNA-based diagnostic panel, ONCOaccuPanel DNA, allowing clinicians to perform simultaneous tests for more comprehensive insights.

ONCOaccuPanel RNA is currently supplied to Asan Medical Center, with plans to expand availability to three regional cancer hospitals by the end of the year. NGeneBio has also partnered with Bayer Korea to promote the panel, alongside Bayer’s multi-cancer targeted therapy, Vitrakvi (ingredient: larotrectinib), to increase market reach.

“The ONCOaccuPanel RNA is designed to test more genes than competing products worldwide, enabling simultaneous DNA and RNA analysis,” NGeneBio CEO Choi Dae-chul said. “This allows for personalized treatment through accurate diagnostics, fulfilling our goal of setting a new standard in Korea’s precision diagnostic platforms.”

The company aims to secure a leading position in both the local and global precision medicine markets, Choi added.